BLLN
NASDAQ:BLLNNASDAQ
4 announcements
Credibility Score76%
BillionToOne Responds to Inaccurate and Misleading Short Seller Report
RoutineModerate hypeunclear
BillionToOne rebuts short-seller allegations but offers no new data or evidence.
18 Nov 2026, 21:05 UTC
▼
BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study Finds
OverhypedModerate hypeunclear
Northstar Response matched or outperformed a leading ctDNA assay with 94% concordance in real-world data.
7 Oct 2026, 11:09 UTC
▼
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
Overhypedunclear
Strong clinical data, but no financials or adoption metrics for NASDAQ:BLLN’s new test.
18 Aug 2026, 16:12 UTC
▼
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
Genuine Signalunclear
Strong clinical data, but no financials or commercial traction—watch, don’t chase yet.
29 Jun 2026, 16:45 UTC
▼